Alx Oncology Holdings Inc (NASDAQ: ALXO) kicked off on Friday, down -7.06% from the previous trading day, before settling in for the closing price of $1.63. Over the past 52 weeks, ALXO has traded in a range of $1.19-$17.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -43.84% over the past five years. While this was happening, its average annual earnings per share was recorded 26.31%. With a float of $30.92 million, this company’s outstanding shares have now reached $52.74 million.
Let’s look at the performance matrix of the company that is accounted for 72 employees. In terms of profitability, gross margin is 74.15%, operating margin of -6446.65%, and the pretax margin is -6095.12%.
Alx Oncology Holdings Inc (ALXO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Alx Oncology Holdings Inc is 41.38%, while institutional ownership is 55.64%. The most recent insider transaction that took place on Jan 06 ’25, was worth 3,998. In this transaction Interim CFO of this company sold 2,221 shares at a rate of $1.80, taking the stock ownership to the 87,902 shares. Before that another transaction happened on Dec 30 ’24, when Company’s Interim CFO sold 1,426 for $1.58, making the entire transaction worth $2,253. This insider now owns 90,123 shares in total.
Alx Oncology Holdings Inc (ALXO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.6 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 26.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.59% during the next five years compared to -50.98% drop over the previous five years of trading.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Trading Performance Indicators
Take a look at Alx Oncology Holdings Inc’s (ALXO) current performance indicators. Last quarter, stock had a quick ratio of 4.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.98, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.50 in one year’s time.
Technical Analysis of Alx Oncology Holdings Inc (ALXO)
Alx Oncology Holdings Inc (NASDAQ: ALXO) saw its 5-day average volume 2.3 million, a positive change from its year-to-date volume of 1.27 million. As of the previous 9 days, the stock’s Stochastic %D was 49.94%. Additionally, its Average True Range was 0.19.
During the past 100 days, Alx Oncology Holdings Inc’s (ALXO) raw stochastic average was set at 27.65%, which indicates a significant decrease from 28.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 105.58% in the past 14 days, which was higher than the 98.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5819, while its 200-day Moving Average is $5.3416. Nevertheless, the first resistance level for the watch stands at $1.5600 in the near term. At $1.6050, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6600. If the price goes on to break the first support level at $1.4600, it is likely to go to the next support level at $1.4050. The third support level lies at $1.3600 if the price breaches the second support level.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Key Stats
The company with the Market Capitalisation of 79.91 million has total of 52,743K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -160,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -30,710 K.
